"Survival Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
| Descriptor ID |
D016019
|
| MeSH Number(s) |
E05.318.740.998 N05.715.360.750.795 N06.850.520.830.998
|
| Concept/Terms |
Survival Analysis- Survival Analysis
- Analysis, Survival
- Analyses, Survival
- Survival Analyses
|
Below are MeSH descriptors whose meaning is more general than "Survival Analysis".
Below are MeSH descriptors whose meaning is more specific than "Survival Analysis".
This graph shows the total number of publications written about "Survival Analysis" by people in this website by year, and whether "Survival Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 5 | 5 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Survival Analysis" by people in Profiles.
-
Investigating non-inferiority or equivalence in time-to-event data under non-proportional hazards. Lifetime Data Anal. 2023 07; 29(3):483-507.
-
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res. 2021 08 18; 23(1):86.
-
Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer. Arch Gynecol Obstet. 2020 04; 301(4):1027-1035.
-
miR-518a-3p Suppresses Triple-Negative Breast Cancer Invasion and Migration Through Regulation of TMEM2. Technol Cancer Res Treat. 2020 Jan-Dec; 19:1533033820977523.
-
Transcriptional Signature Derived from Murine Tumor-Associated Macrophages Correlates with Poor Outcome in Breast Cancer Patients. Cell Rep. 2019 10 29; 29(5):1221-1235.e5.
-
Resuscitation room management of critically ill nontraumatic patients in a German emergency department (OBSERvE-study). Eur J Emerg Med. 2018 Aug; 25(4):e9-e17.
-
Concomitant mitral regurgitation and aortic stenosis: one step further to low-flow preserved ejection fraction aortic stenosis. Eur Heart J Cardiovasc Imaging. 2018 05 01; 19(5):569-573.
-
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol. 2018 05 01; 36(13):1308-1316.
-
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. J Clin Oncol. 2018 02 10; 36(5):454-462.
-
Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. Br J Haematol. 2018 01; 180(1):82-89.
MeSH information
